Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Where Is The Patient Voice In Alzheimer's Disease Drug Development?

This article was originally published in Scrip

Executive Summary

Companies developing treatments for Alzheimer's disease and other types of dementia are failing to incorporate the patient voice in their drug development plans, said Marc Wortmann, Executive Director, Alzheimer's Disease International, in an interview with Scrip.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register